FORM 3

# **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

#### OMB APPROVAL OMB Number 3235-0104 Estimated average burden hours per response: 0.5

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Cheng Jennifer C.			2. Date of Even Requiring State (Month/Day/Yea	ment	3. Issuer Name and Ticker or Trading Symbol Adverum Biotechnologies, Inc. [ ADVM ]					
			02/09/2017		<ol> <li>Relationship of (Check all applica</li> </ol>	( )	(Mo	5. If Amendment, Date of Original Filed (Month/Day/Year)		
C/O ADVERUM BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE					Director  X Officer (give title below)  General Cou		10% Owner Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One	
(Street) MENLO PARK	CA	94025							Form filed b	
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)					Amount of Securities Beneficially Owned (Instr. 4)		1		Nature of Indirect Beneficial Ownership (Instr. 5)	
Common Stock					107,713		D			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		d 3. Title and Amount of Secur Underlying Derivative Secur			4. Conversion or	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
			Date Exercisable	Expiration Date	Title		Amount or Number of Shares	or Derivative Security of		
Stock Option (Right to Buy)		(1)	06/04/2025	Common Stock		15,000	40.28	D		
Stock Option (Right to Buy)		(2)	09/19/2026	Commo	n Stock	35,000	4.09	D		
Stock Option (Right to Buy)		(3)	02/08/2027	Commo	n Stock	72,000	2.7	D		

### **Explanation of Responses:**

- 1. 25% of the shares subject to the option vested and became exercisable on June 5, 2016, and the remaining shares vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- 2. 25% of the shares subject to the option vest and become exercisable on September 20, 2017, and the remaining shares vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- 3. 25% of the shares subject to the option vest and become exercisable on February 9, 2018, and the remaining shares vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

#### Remarks:

/s/ Jennifer C. Cheng, Ph.D., <u>J.D.</u>

03/09/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.